Zelun BioPharma, Founded by Professor Chen Lijuan, Completes Series B Financing and Submits IPO Prospectus
Zenitar
Innovative Drug R&D and Industrialization Service Provider
Source: MedView
November 24,Zenitar Biopharmaceutical Technology Co., Ltd.(hereinafter referred to as "Zenitar")Announced the successful completion of Series B financing in recent times. This round of financing was led byChengdu Sci-Tech Innovation Investment Management's Precision Medicine Industry Innovation FundLeading investment,Huajin Capital, Ceyuan Capital, Shengzhong Investmentand other investment institutions participated together,Chuan Venture CapitalContinued Investment Boost. The funds from this round of financing will be used to advance the Phase 2/3 clinical development of Zenitar's two products and expedite research on the company’s core technology platforms and other R&D pipelines.
Zenitar is a company originating from the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University.Professor Chen Lijuan Leads EntrepreneurshipEstablishA technology-based enterprise focusing on the development of original Class 1 new drugs. According to the press release from Zenitar, the company leverages the multidisciplinary research advantages of Sichuan University and West China Hospital, and collaborates with the listed company Guizhou Bailong, guided by technological innovation.Focusing on unmet clinical needs, concentrating on areas such as malignant tumors, inflammation, and autoimmune diseases., committed to discovering, developing, and commercializing innovative drugs that are potentially "first-in-class" and "best-in-class."
Image Source:Zenitar Official Website
Founder and Chairman of ZenitarProfessor Chen LijuanStated: "In the context of a cooling capital market in the global pharmaceuticals industry, with significant declines in both the number of biopharmaceutical financing events and the amount of funding, Zenitar is very grateful for the investors' high recognition of the company's R&D achievements and development potential, as well as the continued strong support from existing shareholders. The funds raised in this round will primarily support the rapid advancement of several core products that have entered clinical trials."
General Manager of Huaxi Precision Medicine Industry Innovation Center Co., Ltd.Dr. Yuan ShulanRepresentative: "As one of the exemplary cases of West China Hospital's scientific and technological achievements being valued and invested as equity, Zenitar has embarked on an exploratory path for the transformation of scientific and technological achievements. Positioned at the forefront of biopharmaceutical R&D, it is committed to building a full chain of new drug development. Within the framework of 'building circles and strengthening chains,' Zenitar accurately positions itself, persistently engages in independent innovation, and seeks significant breakthroughs in innovative drugs, aligning with China's innovation-driven development strategy. With the close integration of capital and technology, Zenitar is believed to progress faster and further, continuously achieving new technological breakthroughs and realizing high-quality development."
Executive Director of Huajin CapitalDr. Li QiangZenitar focuses on unmet clinical needs in areas such as oncology and inflammatory diseases. Its drug molecular design is significantly differentiated, with multiple pipelines already in the mid-to-late stages of clinical trials, demonstrating excellent clinical data and possessing 'best-in-class' potential. The company's R&D platform is well-established, with abundant clinical resources, making it a Biotech enterprise with strong development prospects.
General Manager of Ce Yuan CapitalLi XiaoboRepresentative stated: "As a high-quality local enterprise in the High-Tech Zone, Zenitar aligns with the 'building circles and strengthening chains' industrial planning of the High-Tech Zone's medical sector. As the first company in the Frontier Medicine Center to adopt the PI + publicly listed company model, Zenitar leverages the robust scientific research advantages of West China Medical School of Sichuan University and the State Key Laboratory of Biotherapy. Founder Professor Li-Juan Chen brings extensive experience in new drug R&D, a solid foundation in research, strong execution capabilities, and several pipelines have already achieved excellent clinical data, demonstrating 'best-in-class' potential."
Assistant to the General Manager of Chuan Venture CapitalDr. Guojun ChenZenitar's team has strong execution capabilities, rapidly achieving multiple milestones under the leadership of Professor Chen Lijuan. The company focuses on clinical needs, emphasizes differentiated competition, and has already shown promising data. It is believed that with the collective efforts of the team, Zenitar will stand out among numerous innovative pharmaceutical companies.
Disclaimer:
The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints presented, and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content included. Readers are advised to use it only as a reference and assume full responsibility for their actions. The various articles published by this official account focus on sharing; if there is any infringement, please contact us, and we will delete them.
Booths for the Class of 2024 are now available for booking!
(Sponsorship forms include but are not limited toSpeaking slots, exhibition booths, color pages in conference proceedings, dinner sponsorship, promotional conference materials, etc.)
Scan the code to consult immediately!
Phone: 17521760400
Email: marketing@truesaw.com
